In this episode, Kelvin Stott talks about why might be pharma's business model broken and how can it be fixed, the declining ROI on drug R&D, better R&D portfolio decision making, raising the bar in pharma/biotech innovation and more. 

Kelvin Stott has over 20 years of diverse leadership experience in pharma R&D strategy and operations, drug discovery and development, portfolio management, strategy consulting, biotech start-ups and venture capital. Currently, he is the Founder and CEO of Amporin Pharmaceuticals.

If you want to connect with us:
Linkedin: https://www.linkedin.com/company/cures-capital-podcast

YouTube - watch the interview:
https://www.youtube.com/@CuresCapital

If you want to connect with Kelvin or follow up on some of his work:
Linkedin: https://www.linkedin.com/in/kelvinstott/
Amporin Pharmaceuticals: https://www.linkedin.com/company/amporin/

Article: Pharma's broken business model - Part 1: An industry on the brink of terminal decline
Link: https://www.linkedin.com/pulse/pharmas-broken-business-model-industry-brink-terminal-kelvin-stott/

Article: Pharma's broken business model - Part 2: Scraping the barrel in drug discovery
Link: https://www.linkedin.com/pulse/pharmas-broken-business-model-part-2-scraping-barrel-kelvin-stott/

Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

In this episode, Dr. Jack Scannell delves into topics such as R&D productivity, decision-making, model validity, and more.

If you're looking to deepen your understanding of these areas, there's no better guide than Jack.

Jack brings a deep and holistic understanding of the biotech and pharma industry, having held a variety of roles—including being a neuroscientist, strategy consultant, investment analyst, and now the CEO of Etheros Pharmaceuticals.

Chapters:
00:00 Intro
02:08 Guest introduction - Dr. Jack Scannell
05:46 R&D productivity from past to present to future
34:00 Decision making, model validity and quality
56:00 Practitioner's view and advice
01:04:04 Closing remarks with Jack
01:05:45 Episode summary and discussion with Martin and Simon

If you want to connect with us:
Linkedin: https://www.linkedin.com/company/cures-capital-podcast

YouTube - watch the interview:
https://www.youtube.com/@CuresCapital

If you want to connect with Jack or follow up on some of his work:
Linkedin: https://www.linkedin.com/in/jack-scannell-554b28/
X: https://x.com/jackscannell13
Etheros Pharmaceuticals: https://etherospharma.com

Paper: Diagnosing the decline in pharmaceutical R&D efficiency Link: https://www.nature.com/articles/nrd3681

Paper: Predictive validity in drug discovery: what it is, why it matters and how to improve it Link: https://www.nature.com/articles/s41573-022-00552-x

Paper: When Quality Beats Quantity: Decision Theory, Drug Discovery, and the Reproducibility Crisis Link: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0147215

Paper: Performance assessment and economic analysis of a human Liver-Chip for predictive toxicology (Novel approach to DCF valuation of biopharma assets is here in Supplementary Data 2 of the paper) Link: https://www.nature.com/articles/s43856-022-00209-1

Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.

EPISODE 1 - Cures & Capital: Trailer Episode

In this episode, we introduce the scope and mission of the podcast.

Our focus with Cures & Capital is the intersection between drug R&D and finance. 

Hosts: Martin Slezak & Simon Birksø.

Disclaimer: This podcast and activities related to it are completely independent from our day jobs. All the views and opinions expressed through this channel are solely our own and do not represent or in any way reflect the views and opinions of the companies we work for.